The company’s net profit in the third quarter of 2021 was $8.15 billion (about 7 billion euros). This is a more than five-fold increase compared to the same period last year, when the company made a profit of 1.47 billion (€1.27 billion). And the company’s sales increased by 134 percent: from 10.28 billion to 24.09 billion dollars, or about 21 billion euros.
Revenues of the Corona vaccine for Pfizer amounted to 12.98 billion dollars (about 11.2 billion euros). For the full fiscal year, 2.3 billion doses of vaccines are now expected to be delivered, which together represents sales of nearly $36 billion, or €31 billion. This expectation has been revised up, in part due to the boosted shots. To date, a turnover of 28.9 billion euros has been assumed.
Even without the Corona vaccine, Pfizer’s revenue continued to rise by 11 percent. The company also revised its total revenue forecast for 2021 and beyond. The annual turnover is now assumed to be between 81 billion and 82 billion euros (or 70.7 billion euros), instead of 78 billion to 80 billion dollars (about 68.9 billion euros).
The decline in the sale of corona vaccines has already been taken into account for the next year. Pfizer expects to generate sales of €25 billion in 2022 from 1.7 billion doses.
“Total coffee specialist. Hardcore reader. Incurable music scholar. Web guru. Freelance troublemaker. Problem solver. Travel trailblazer.”
More Stories
Bitcoin fell below $60,000 after the Israeli counterattack, but is recovering
Samsung switches to a six-day work week
Are there enough charging stations and can the electricity grid handle them? The five most frequently asked questions about electric driving